Research programme: recombinant human fibrinogen - Pharming

Drug Profile

Research programme: recombinant human fibrinogen - Pharming

Alternative Names: rhFIB

Latest Information Update: 31 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharming Group NV
  • Class Acute-phase proteins; Blood coagulation factors; Protein precursors; Recombinant proteins
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Research Afibrinogenaemia

Most Recent Events

  • 31 Dec 2008 Early research is ongoing in the Netherlands
  • 16 Oct 2007 Early research in Afibrinogenaemia in the Netherlands (Parenteral)
  • 16 Oct 2007 The recombinant human fibrinogen product receives orphan drug status for the treatment of bleeding in patients deficient in fibrinogen in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top